Skip to main content
CELGinactive

CELGENE CORP /DE/

Biopharma developer (SEC filing verified)·Commercial
OncologyRare DiseaseNeurologyImmunologyDermatologyHematology

CELG evidence brief

What we can confirm

BioSniper Score:
6.9 / 10
Lead Asset:
luspatercept (Phase 3)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.9 / 10 · Lead Asset: luspatercept (Phase 3)
BioSniper AIPage evidence connected

Prepared research question

What matters most for CELG—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.9/10

BioSniper Score

Based on 3 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

luspatercept (Phase 3)

Next Catalyst

—

Financial data as of Sep 30, 2019.

Tracking 2 pipeline candidates · 1 clinical trial · 1 FDA decision for CELGENE CORP /DE/.

Run CELGENE CORP /DE/ through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available CELGENE CORP /DE/ facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 3 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial Health6.1

D/E 2.42 · 3% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

What is CELGENE CORP /DE/'s lead drug candidate?

CELGENE CORP /DE/'s most advanced tracked candidate is luspatercept (Phase 3) for low-to-intermediate risk myelodysplastic syndromes (MDS), transfusion-dependent beta-thalassemia, myelofibrosis.

What therapeutic areas does CELGENE CORP /DE/ focus on?

CELGENE CORP /DE/ develops therapies across Oncology, Rare Disease, Neurology, Immunology, Dermatology, Hematology.

923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.